News UCB recruits Belgian wearables firm for epilepsy study Byteflies' Sensor Dot will help monitor brain, heart and respiration activity.
News FDA rejects Amgen/UCB osteoporosis drug The FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a potential cardiac safety risk.
News Safety restrictions spell the end for Servier osteoporosis d... Sales of Protelos hit by safety restrictions.
News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News Pfizer's fast-tracked leukaemia candidate could rival CAR-Ts Antibody-drug conjugate with FDA gets six-month review.
News Amgen/UCB reveal new osteoporosis drug data But romosozumab missed secondary endpoint of non-vertebral fractures
News As Ebola deaths climb, search begins for vaccine The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola and fast-track clinical trials.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
